Latest Funding News

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

AVADA Group Limited reported a significant net loss of $17.6 million for FY25, driven by major impairments in New Zealand and New South Wales operations amid challenging market conditions. The company completed a strategic consolidation of its Australian businesses and appointed new senior management to steer operational transformation.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

Investor Centre Limited delays its 2025 Annual Report following the liquidation of key funder Amram Corp, triggering a likely trading suspension.

Australian Agricultural Projects Limited reported a strong 18% revenue increase and a 56% jump in net profit for FY2025, while preparing to directly manage a key orchard segment after lease changes.

Axiom Properties Limited reports a 55% reduction in net loss for FY25, completing its Glenlea Estate sales and accelerating its Property Technology strategy with a $30 million debt facility for PaySure.

Pengana Global Private Credit Trust (PCX) has delivered a solid first-year performance, achieving an 8.41% total return driven by a 7.04% cash yield and NAV growth. The Trust also increased monthly distributions and declared a special payout, underscoring its commitment to stable income and capital preservation.

RBR Group Limited reported an 88% plunge in revenue and a widening net loss for FY2025, impacted by political instability and LNG project delays in Mozambique. The company is investing in facility upgrades and workforce training to position itself for a market rebound.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.

Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.

Livium Ltd reports a maiden profit at its battery recycling arm Envirostream, advances its lithium extraction joint venture with Mineral Resources, and secures a $30 million grant for its lithium ferro phosphate demonstration plant.